top of page
Search

Align Technology: not going down on bad numbers

  • Writer: Abacus Research
    Abacus Research
  • Aug 15, 2022
  • 1 min read

Align is a dental consumer products company that has been struggling in the post Covid world.

  • 2022 downgrades were part of the pandemic dislocation & management’s over-optimism.

  • We believe, ALGN’s business model and competitive position have not been impaired.

  • We see the potential for earnings growth to rebound to 30% over 2022-25 driven by a recovery in revenue growth and operating margins.

  • The multiple is below historical average and low relative to peers, hence why we see 78% upside potential over a couple of years.

Potential Upside: $514 (+78%)

Sensible Downside: $230(-20%)


 
 
 

Recent Posts

See All
Axon:

Axon is shifting from selling individual tools to providing an interconnected ecosystem. Hardware like TASERs and cameras now act as "data generators" that feed directly into high-margin software modu

 
 
 
C.H. Robinson

CHRW has been going through significant change, They are retaking market share. The new CEO has transformed the company by bringing in a lean / AI, that has helped CHRW to grow earnings despite strugg

 
 
 
Brookfield (BN):

We initially wrote up BN in Jan 2024, it has increased 70%, so why mention it again? Firstly, we think the fundamentals are as good now as they were 2 yrs ago, with a >15% IRR on offer. BN is not a we

 
 
 

Comments

bottom of page